Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, announces an oral ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback